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Role of interleukin-6 in b2-microglobulin–induced bone min- [1]. Increased synthesis and release of b2m, as indicated
eral dissolution. by an elevation of serum and urine b2m concentrations,
Background. b2-microglobulin (b2m) amyloidosis is com- occurs in a variety of disease states, including rheumaticmonly seen in patients undergoing long-term dialysis. b2m has
disorders, infectious diseases, acquired immunodeficiency,been shown to induce in vitro bone mineral dissolution. The
and lymphoproliferative and renal diseases [2–11]. Se-present study was designed to investigate the effect of b2m on
osteoblast function and the role of interleukin-6 (IL-6) on b2m- rum and tissue concentrations of b2m are probably the
induced bone resorption. highest in patients with end-stage renal disease caused
Methods. Using neonatal mouse calvariae as well as primary by impaired clearance in addition to increased produc-osteoblasts and MC 3T3 osteoblast-like cells, IL-6 production,
tion. In patients with end-stage renal disease, b2m devel-release, and gene expression were investigated with enzyme-
ops into amyloid deposits in the periarticular bones andlinked immunosorbent assay (ELISA) and semiquantitative
reverse transcription-polymerase chain reaction (RT-PCR) tech- adjacent structures, leading to a destructive osteoarthrop-
niques, respectively. athy. The incidence of dialysis-related amyloidosis (DRA)
Results. In calvariae, b2m induced a time- and dose-depen- correlates with the age of the patient and duration of renaldent calcium release, which was maximum following a 48-hour
failure [6, 8]. Unfortunately, DRA is a common compli-incubation at a concentration of 1025 mol/L. b2m (1026 mol/L)
also induced a significant release of IL-6 from calvarial and cation and has become a major source of morbidity
primary osteoblastic cultures. Using 1026 mol/L b2m, the amount among patients undergoing long-term dialytic therapy.
of IL-6 mRNA in MC 3T3 cells increased in a time-dependent Recent evidence suggests that b2m may have a patho-fashion, which peaked at 3 hours and declined to baseline by
physiologic role in bone remodeling. We have demon-12 hours. In primary osteoblast cells, b2m maximally increased
strated that b2m induces a dose-dependent net calciumIL-6 mRNA levels at 6 hours; however, they remained elevated
up to 24 hours. Compared with control, the presence of b2m efflux from cultured neonatal mouse calvariae [12, 13].
significantly increased cell proliferation of both primary osteo- This calcium efflux is due, in part, to osteoclastic stimula-
blasts and MC 3T3 cells. To investigate osteoblastic function tion, as the effect of b2m can be inhibited by calcitoninfurther, osteocalcin mRNA was quantitated. Incubation with
[12] and partially blocked by both anti–interleukin-1bb2m for 3 to 24 hours did not alter the amount of osteocalcin
(anti–IL-1b) antibody and the IL-1 receptor antagonistmRNA in the MC 3T3 osteoblast cells.
Conclusion. b2m affects bone metabolism by mechanisms [14]. The advanced glycation end product (AGE) modi-
that include increasing IL-6 gene expression and release, and fication of b2m results in a greater calcium efflux from
enhancing osteoblast proliferation without affecting osteocal- cultured calvariae than that of unmodified b2m [15] andcin gene expression.
appears to stimulate in vitro osteoclastic bone resorption
directly [16]. The mechanism of b2m-associated bone loss
is most likely mediated by cytokines and other local bone
b2-microglobulin (b2m), an 11.8 kD protein, is the growth factors. In addition to our previous report dem-small extracellular immunoglobulin-like subunit of the
onstrating a role of IL-1 in b2m-induced bone loss, b2mmajor histocompatibility complex (MHC) class I molecule
increases the release of IL-1b, tumor necrosis factor-a
(TNF-a), and IL-6 from monocytes/macrophages [15,
17, 18]. The levels of cytokines produced are sufficientKey words: bone resorption, calvariae, osteoblasts, amyloidosis, dial-
ysis, cystic bone lesions. to stimulate collagenase synthesis in cultured human sy-
novial cells [15, 17, 18].Received for publication March 18, 1999
Cytokines, such as IL-1, IL-6, and TNF-a, have multi-and in revised form October 27, 1999
Accepted for publication November 1, 1999 ple effects in bone, including mediation of bone resorp-
tion [19–22]. b2m-induced bone resorption appears toÓ 2000 by the International Society of Nephrology
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be mediated in part by IL-1, and IL-1 induces bone
resorption by stimulating IL-6 [14, 23]. Thus, to deter-
mine whether IL-6 mediates the bone-resorbing effects
of b2m, the effect of b2m on IL-6 release and gene expres-
sion in cultured calvariae and bone cells was determined.
METHODS
Organ culture of bone
Calvariae of five- to seven-day-old CD-1 Swiss mice
were removed and cultured as previously described [12,
14, 15, 24–27]. All animal procedures were conducted in
accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals. Following
dissection, calvariae were preincubated in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
15% horse serum, 2.8 mmol/L l-glutamine, 50 IU/mL
potassium penicillin, and 50 mg/mL streptomycin (GIBCO
BRL, Gaithersburg, MD, USA) for 18 hours at 378C for
equilibration and removal of cytokines released during
dissection. Pairs of calvariae were then placed in 35 mm
Petri dishes containing 2 mL of the previously mentioned
medium with the appropriate treatment or vehicle, which
had been preincubated for one hour for equilibration.
Bone cultures were then incubated in control or experi-
mental media for 24 to 72 hours, and aliquots of medium
were obtained for subsequent analysis. Fig. 1. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) analysis of b2-microglobulin (b2m). b2m (5 mg; lane 1)
was analyzed on a 4.5% stacking and 15% resolving polyacrylamideOsteoblastic cultures
gel under denaturing conditions and was subsequently stained using
Isolation of primary osteoblasts was performed using GelCode Blue (Pierce, Rockford, IL, USA). Molecular weight markers
(lane 2) indicate 46 K, 30 K, 21.5 K, 14.3 K, 6.5 K, and 3.4 K, respectively.five- to seven-day-old mice. The hind limb bones were
removed, minced with a scalpel into small pieces, and
pipetted into 5 mL of HEPES-supplemented DMEM to
release osteoblasts. Cells were filtered using a sterile 30
cells. Primary osteoblasts or MC 3T3 osteoblast-like cells
mm nylon filter and allowed to settle onto 22 mm diameter
were plated in culture medium and incubated for 18round cover slips for 30 minutes. The medium was then
hours for equilibration and settling. Calvarial incuba-replaced with fresh culture medium [DMEM supple-
tions were set up as described previously in this article.mented with 10% fetal bovine serum (FBS), 2.8 mmol/L
The calvariae or cells were incubated in the appropriatel-glutamine, 50 IU/mL potassium penicillin, 50 mg/mL
experimental [either purified human b2m, Cortex Bio-streptomycin, and 2.5 mg/mL amphotericin B; GIBCO
chem, Inc., San Leandro, CA, USA; mouse IL-1b, Endo-BRL] and incubated for 60 minutes at 378C. The osteo-
gen Inc., Woburn, MA, USA; bovine parathyroid hor-blastic nature of the cells was confirmed by staining for
mone (PTH) 1-34, Bachem, Torrance, CA, USA] oralkaline phosphatase and the production of osteocalcin
control media. Incubation periods ranged from 3 to 72following stimulation with vitamin D.
hours. Following the incubation period, the supernatantsMC 3T3 clone E1 cells were obtained from Riken Gene
were collected for analysis, and the total RNA was iso-Bank Cell Bank (Tsukuba Science City, Japan) and were
lated from cells. Collected supernatants and RNA sam-cultured in a-MEM supplemented with 10% fetal bovine
ples were either used immediately or stored at 2808Cserum, 50 IU/mL potassium penicillin, and 50 mg/mL
until analyzed.streptomycin. Cells were all negative for mycoplasma by
Purified human b2m (Cortex Biochem, Inc.) was ana-DAPI (4,6-Diamidino-2-Phenylindole) staining (Sigma,
lyzed using sodium dodecyl sulfate-polyacrylamide gelSt. Louis, MO, USA).
electrophoresis (SDS-PAGE) to ensure purity (Fig. 1).
Experimental conditions b2m (5 mg) was subjected to electrophoresis on a 4.5%
stacking and 15% resolving polyacrylamide gel underExperimental incubations were performed using cal-
variae, primary osteoblasts, and MC 3T3 osteoblast-like denaturing conditions and subsequently stained using
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GelCode Blue (Pierce, Rockford, IL, USA). No contam- were obtained from Stratagene (La Jolla, CA, USA).
Osteocalcin primers were used as previously publishedinating proteins were detected, and the only band corre-
sponded to b2m. [28]. To standardize the amount of message of interest
(IL-6 or osteocalcin) to the internal control (b-actin),
Interleukin-6 ELISA assays two-step PCR was performed [29]. Briefly, the cycle
number for the linear phase of the PCR reaction wasAt the end of the appropriate incubation period, IL-6
was determined from the supernatants using a mouse- determined for each set of primers and was found to be
a total of 26 cycles for IL-6, 30 cycles for osteocalcin,specific IL-6 enzyme-linked immunosorbent (ELISA) kit
(R&D Systems Inc., Minneapolis, MN, USA). and 16 cycles for b-actin. The two-step PCR reaction
was started with preincubation for five minutes at 948C
Calcium measurements and then for five minutes at 608C in the presence of
primers specific for IL-6 or osteocalcin, and the reactionThe calcium concentration of the culture medium be-
fore and after the incubation period was determined by was then subjected to 10 cycles (IL-6) or 14 cycles (osteo-
calcin). The cycle conditions were as follows: 948C forautomated fluorometric titration analysis (Calcette; Preci-
sion Systems, Sudbury, MA, USA) as previously described 45 seconds, 608C for 45 seconds, and 728C for 90 seconds.
Primers specific for b-actin were then added to each[12, 14, 15, 24–27]. The net calcium flux was calculated
using the following equation: Jca 5 Vm (Cf 2 Ci), where tube, and the reaction was subjected to an additional 16
cycles. Using the two-step PCR method, reactions wereVm is the medium volume (2 mL), and Cf and Ci are the
final and initial calcium concentrations, respectively, in run in the linear phase for both the message of interest
and the internal control, in the same tube. Ampliconsnanomoles per bone per incubation time. A positive flux
(efflux) indicates movement of calcium from bones into were subjected to agarose gel electrophoresis and stained
with ethidium bromide. The density of the IL-6, osteocal-medium, and negative flux (influx) the movement from
medium to bone. cin, and b-actin amplicon bands was visualized by inte-
grating ultraviolet light using the Eagle Eye camera sys-
Proliferation assay tem (Stratagene). The amount of the IL-6 or osteocalcin
message was expressed as percentage of b-actin.Osteoblasts were plated onto 96-well plates and equili-
brated for 18 hours. To make cells quiescent, culture
Statistical analysismedium was changed to serum-free DMEM containing
1% bovine serum albumin (BSA) for 24 hours. Treat- Tests for significance of differences between group
means were performed using a t-test when only two groupsments (b2m or vehicle) were added in the same medium
and incubated for 72 hours. Proliferation of cells was were involved and ANOVA with a postpriori multiple
comparison if more than two groups were involved. Quan-measured using the CellTiter 96 Aqueous One Solution
Cell Proliferation Assay, following the manufacturer’s titative dose response curves were analyzed by ANOVA
for parallel line assays. All calculations were performedinstructions (Promega, Madison, WI, USA). Briefly, at
the end of the incubation period, a tetrazonium compound using the statistical analysis package SYSTAT (Evanston,
IL, USA) on a 486 IBM-compatible personal computer.was added to the cells for one to four hours. Tetrazonium
compound was bioreduced by metabolically active cells A P value of less than 0.05 was considered significant.
into a colored formazan product that was detected by
absorbance at 490 nm. Cellular proliferation was ex-
RESULTS
pressed as a percentage of vehicle-treated control.
Effect of b2-microglobulin on calcium release and
interleukin-6 production of cultured boneSemiquantitative RT-PCR
Following the appropriate incubation period, total Calvariae from neonatal mice were incubated for both
24 and 48 hours in either control medium, medium sup-RNA was isolated from cells using the commercially avail-
able TRIzol reagent (GIBCO BRL), following the manu- plemented with b2m (1028 to 1025 mol/L), parathyroid
hormone (PTH; 1028 mol/L), or IL-1 (5 ng/mL), and thefacturer’s instructions. First-strand cDNA was generated
in a 12 mL reaction using 5 mg total RNA and random calcium flux was determined (Fig. 2). Compared with
control, the presence of b2m at concentrations of 1028hexamers with the SuperScript preamplification system
(GIBCO BRL), according to the manufacturer’s instruc- to 1026 mol/L for 24 hours did not significantly increase
calcium efflux from the cultured bone. However, 1025tions. PCR reactions were performed using mouse-specific
reverse transcription-polymerase chain reaction (RT- mol/L b2m significantly increased calcium efflux from
bone (b2m 5 252.7 6 39.5 nmol/bone/24 h). The maxi-PCR) primers at a concentration of 0.4 mmol/L, along
with Ready-To-Go PCR Beads (Amersham Pharmacia mum calcium efflux achieved with b2m following a 24-
hour incubation was approximately half of that observedBiotech, Arlington Heights, IL, USA), according to the
manufacturer’s instructions. Primers for IL-6 and b-actin with both PTH and IL-1. Following a 48-hour incubation,
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Fig. 2. Dose and time dependence of the b2m effect on calcium release
from bone. Neonatal mouse calvariae were incubated for 24 (h) or
48 hours (j) in either control medium, medium supplemented with
increasing concentrations of b2m, 1028 mol/L parathyroid hormone
(PTH), or 5 ng/mL interleukin-1 (IL-1), and calcium flux was determined
(nmol/bone/time). Compared with controls, b2m induced a time- and
dose-dependent increase of calcium release from bone. At 48 hours
and a concentration of 1025 mol/L is comparable to that observed with
both PTH and IL-1. Data are expressed as means 6 SEM and represent
six to eight pairs of calvariae per treatment group. (*) Different than
control, during same time; P , 0.05.
Fig. 4. IL-6 release from osteoblasts. Primary osteoblasts (A) and MC
3T3 cells (B) were incubated with or without b2m (1026 mol/L) for 24
to 72 hours, and IL-6 release was determined using a mouse-specific
ELISA (N 5 8 per treatment group). In the primary osteoblasts, the
Fig. 3. b2m induced release of IL-6 from calvariae. Neonatal mouse presence of b2m (j) resulted in a significant increase of IL-6 release
calvariae were incubated with or without b2m (1026 mol/L) for 48 hours, from cells throughout the incubation period. In the MC 3T3 cells, b2m
and the calcium flux (h), as well as IL-6 release (j), was determined. (1026 mol/L) did not alter the IL-6 release. Data are expressed as
Compared with control, b2m increased both calcium and IL-6 release means 6 SEM. (*) Different from control, same time; (1) different
from cultured bone. Data are expressed as means 6 SEM and represent from 24 hours, same treatment; P , 0.05.
six to eight pairs of calvariae per treatment group. (*) Different than
control; P , 0.05.
trol, b2m significantly increased both the release of cal-
cium and IL-6.
b2m significantly increased the calcium efflux at concen-
trations of 1026 and 1025 mol/L. At a b2m concentration Effect of b2-microglobulin on interleukin-6 release
of 1025 mol/L, the calcium efflux was similar to that from osteoblasts
observed with both PTH and IL-1. Thus, compared with To further evaluate the effect of b2m on the production
control, b2m induced a dose- and time-dependent in- of IL-6 by bone cells, osteoblasts were incubated with
crease in calcium efflux from bone, which, at a concentra- 1026 mol/L b2m for 24 to 72 hours, and IL-6 released
tion of 1025 mol/L, was comparable to that observed into the media was determined using a mouse-specific
with both PTH and IL-1. ELISA (Fig. 4). In primary osteoblast cultures, compared
To determine whether or not b2m affected IL-6 pro- with control, the medium IL-6 concentrations were sig-
duction, calvariae were incubated with or without 1026 nificantly greater in the presence of b2m at all the time
mol/L b2m for 72 hours, and both calcium flux and IL-6 points (Fig. 4A). b2m treatment resulted in a significantly
higher IL-6 release following a 72-hour incubation com-release were determined (Fig. 3). Compared with con-
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Fig. 6. IL-6 mRNA in MC 3T3 cells. MC 3T3 cells were treated with
1026 mol/L b2m or vehicle (Ctl) for 3 to 24 hours. The levels of IL-6
mRNA were evaluated as described in the Methods section. (A) Repre-
sentative ethidium bromide stained gel. (B) Relative amount of IL-6
mRNA standardized to b-actin. Symbols are: (h) control; (j) b2m.
b2m induces a time-dependent increase in the amount of IL-6 mRNA
in MC 3T3 cells. (*) Different than control, at the same time; P , 0.05.
(Fig. 5A). On the other hand, using MC 3T3 cells, treat-
ment with 1026 mol/L b2m did not change cell prolifera-
tion compared with control (Fig. 5B). However, prolifer-
ation of MC 3T3 cells was significantly increased using
1025 mol/L b2m compared with both 1026 mol/L b2m andFig. 5. Effect of b2m on the proliferation of osteoblasts. Quiescent control.primary osteoblasts (A) and MC 3T3 cells (B) were incubated with
increasing concentrations of b2m (1026 mol/L, 1025 mol/L) for 72 hours,
and cell proliferation was determined (N 5 8 per treatment group). Effect of b2-microglobulin on interleukin-6 gene
b2m induces an increase of proliferation in both cell types. Data are expression in osteoblastic cells
expressed as a percentage of control (means 6 SEM). (*) Different
than control; (1) different than 1026 mol/L b2m; P , 0.05. MC 3T3 cells were incubated in the presence or ab-
sence of 1026 mol/L b2m for 3 to 24 hours. Total RNA
was isolated, and RT-PCR was performed. The densities
of the IL-6 and b-actin amplicon bands were measured,pared with the 24-hour treatment. Studies performed
and the percentage of the IL-6 message relative to theusing MC 3T3 osteoblast-like cells demonstrated no ef-
b-actin, which served as an internal control, was deter-fect of b2m on IL-6 release (Fig. 4B).
mined. Compared with control, b2m induced a significant
Effect of b2-microglobulin on the proliferation increase of IL-6 message (Fig. 6). This effect was greatest
of osteoblasts at three hours, decreased following a six-hour incuba-
tion, and was not different from control following eitherQuiescent primary osteoblasts and MC 3T3 cells were
a 12- or 24-hour incubation.incubated in the absence and in the presence of 1026 and
Primary osteoblasts isolated from mouse limb bones1025 mol/L b2m for 72 hours, and cell proliferation was
were incubated in the presence or absence of 1026 mol/Ldetermined (Fig. 5). Using primary osteoblast cells, b2m
induced a dose-dependent increase of cell proliferation b2m for 3 to 24 hours. Total RNA was isolated, and
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Fig. 7. IL-6 mRNA in primary osteoblasts. Primary osteoblasts were Fig. 8. Osteocalcin mRNA in MC 3T3 cells. Primary osteoblasts were
treated with 1026 mol/L b2m or vehicle (Ctl) for 3 to 24 hours. The treated with 1026 mol/L b2m or vehicle (Ctl) for 3 to 24 hours. The
levels of IL-6 mRNA were evaluated as described in the Methods levels of osteocalcin (OC) mRNA were evaluated as described in the
section. (A) Representative ethidium bromide stained gel. (B) Relative Methods section. (A) Representative ethidium bromide stained gel. (B)
amount of IL-6 mRNA standardized to b-actin. Symbols are (h) con- Relative amount of IL-6 mRNA standardized to b-actin. Symbols are
trol; (j) b2m. b2m induces a time-dependent increase in the amount (h) control; (j) b2m. b2m treatment for 3 to 24 hours did not alter the
of IL-6 mRNA in primary osteoblasts. (*) Different than control, same expression of the osteocalcin gene in MC 3T3 cells.
time; P , 0.05.
undergoing long-term dialytic therapy and is associatedRT-PCR was performed. The densities of the IL-6 and
with DRA [6–8]. The specific bone lesions associated withb-actin amplicon bands were measured, and the percent-
DRA include erosive arthropathies with multiple boneage of the IL-6 message relative to the b-actin was deter-
cysts containing b2m-amyloid deposits [9, 10, 30–32]. Themined. Compared with control, b2m induced a significant
increase of IL-6 message at all time points (Fig. 7). This pathophysiologic mechanism resulting in these lesions
effect was greatest after three and six hours and was is poorly understood. b2m, both in its native form and
only slightly less than the maximum following 12- and following AGE modification, is a potent stimulator of
24-hour incubations. Of note, there was still a significant bone resorption [9, 12–16, 18, 33]. Results of previous
induction of IL-6 message following a 24-hour incubation. studies suggest that the effect of b2m on bone involves
a complex interaction with several hormonal and/or local
Effect of b2-microglobulin on the expression of factors of bone remodeling. Using both submaximal and
osteocalcin mRNA from bone cells
pharmacological concentrations of PTH, we were unable
MC 3T3 cells were incubated in the presence or ab- to demonstrate augmentation of calcium efflux from
sence of 1026 mol/L b2m for 3 to 24 hours. Total RNA calvariae incubated with PTH and b2m [12, 13]. Other
was isolated, and RT-PCR was performed (Fig. 8). The investigators were similarly unable to demonstrate an
densities of the osteocalcin and b-actin amplicon bands effect of PTH on b2m transcription or an effect of
were measured, and the percentage of the osteocalcin 1,25(OH)2D3 on b2m immunoreactivity in osteoblasticmessage relative to the b-actin was determined. As illus- cultures [34, 35]. These data suggest that calciotropic
trated in Figure 8, b2m did not alter osteocalcin gene hormones do not directly influence b2m action in bone.expression. Consistent with previous studies [12, 13], the present
study demonstrates that b2m causes a time- and dose-
DISCUSSION dependent calcium efflux from neonatal mouse calvariae.
Since the b2m-induced calcium release from calvariae isAmyloid deposition in bone and synovium is one of the
more prevalent complications observed among patients time dependent, it is likely that local mediators of bone
Balint et al: b2m and IL-6 in bone resorption 1605
remodeling regulate the effect of b2m. In its normal or not change the amount of osteocalcin mRNA in MC 3T3
cells.AGE-modified form, b2m induces the release of bone
resorbing cytokines, such as IL-1b, IL-6, and TNF-a, There is much controversy in the literature concerning
the mitogenic activity of b2m. Taking into account thefrom monocytes/macrophages, as well as stimulates mi-
gration of these cells [17, 18]. The presence of bone cysts similarities between bone-derived growth factor (BDGF)
and b2m in the amino acid composition and identicalin DRA raises the question as to whether they are the
result of increased bone resorption, altered bone forma- amino-terminal sequences, investigators have proposed
that BDGF is b2m [38]. Using murine osteoblast cultures,tion, or both. IL-6 is a cytokine produced by marrow
stromal cells, monocytes/macrophages, and osteoblasts b2m was shown to have a mitogenic effect and stimulate
DNA production, collagen, and noncollagen protein syn-that has a direct effect on both osteoblasts and osteo-
clasts. IL-6 stimulates bone resorption in cultures of fetal thesis similarly to isolated BDGF [35, 38, 39]. Using
isolated chicken osteoblasts, Jennings, Mohan, and Bay-mouse bone in vitro [23] and induces osteoclast forma-
tion in human marrow cultures [36]. IL-6–type cytokines link raised the possibility that the mitogenic effect of
b2m was attributable to contamination with growth fac-affect osteoblast differentiation, whereas IL-6 increases
alkaline phosphatase and decreases osteocalcin activity tors [40]. However, growth factor contamination is highly
unlikely in the present study because the b2m prepara-[37]. IL-6 and the IL-6–type cytokines are capable of
regulating both osteoclastogenesis and osteoblastogen- tion used in the present study was free of additional
proteins (Fig. 1). In earlier studies, using murine calvarialesis, and they play a role in physiologic bone remodeling.
The bone cysts observed in DRA might be the result of cultures, we were unable to demonstrate a mitogenic
effect of human b2m [9]. In the present study, we demon-alteration in bone remodeling. Thus, the aim of the pres-
ent study was to determine the effect of b2m on the strated a growth-promoting effect of human b2m on both
primary osteoblasts and MC 3T3 osteoblast-like cells.metabolism of IL-6 in osteoblasts.
In the present study, we demonstrated that b2m also However, a significant difference was observed in the
sensitivity of primary osteoblasts and MC 3T3 cells. Ainduces the release and gene expression of IL-6 from
bone and bone cells in a dose-dependent fashion. No significant increase of cell proliferation was observed in
the presence of 1026 mol/L b2m using primary osteoblastsb2m receptor has yet been described, and no mechanistic
explanation on cellular action of b2m is available. How- as opposed to MC 3T3 cells that required 1025 mol/L b2m
to represent a similar effect. The differences in sensitivityever, that b2m induced IL-6 gene expression in both MC
3T3 cells and primary osteoblasts within three hours might be related to the developmental phase of the cells
and the purity and homogeneity of the culture. Thissuggests a direct interaction between b2m and the regula-
tory elements of the IL-6 gene. The b2m-induced gene might also explain the differences in mitogenic activity
observed in previous studies.expression of IL-6 returns to baseline levels very quickly
in MC 3T3 osteoblast-like cells. However, it remains The serum level of b2m in healthy individuals is ap-
proximately 1027 mol/L. As shown in Figure 2, 1027 mol/Lelevated in primary osteoblasts. The difference observed
in the time course of the IL-6 gene expression between b2m has no bone resorbing effect. The reduced clearance
of b2m associated with renal failure increases b2m con-the MC 3T3 osteoblast-like cells and primary osteoblasts
was most likely related to subtle differences in the osteo- centrations approximately 50-fold [41]. Thus, the concen-
trations of b2m (1026 to 1025 mol/L) used in the presentblasts’ phenotype as well as to differences in maturation.
The primary osteoblast cultures represent a mixture of study correspond with the serum values of b2m com-
monly observed in patients with DRA. The local b2mcells in different stages of maturation, containing sub-
populations probably more and less sensitive to b2m ac- concentration in the amyloid deposit is likely to be much
higher. Taking into account that even the less sensitivetion, as opposed to the homogeneous cell population of
the MC 3T3 cell line. This might explain, in part, why MC 3T3 cells responded to 1025 mol/L b2m implies that
concentrations in the immediate environment of the os-the different cell types have different sensitivities to pro-
liferation and IL-6 release. The difference observed in teoblasts are capable of altering bone metabolism.
In conclusion, b2m affects bone metabolism in a varietythe time course of the IL-6 gene expression between the
MC 3T3 osteoblast-like cells and primary osteoblasts of ways. This study demonstrates that the bone resorbing
effect of b2m involves an induction of IL-6 productionmight also partly explain the differences observed in IL-6
protein release. from osteoblasts. As previously demonstrated, b2m also
activates monocytes to release bone resorbing cytokinesb2-microglobulin appears to be an active participant
in the bone remodeling process under physiologic condi- and to migrate to the site of the b2m deposition [17, 42],
where the monocytes may further induce the releasetions. Bone cells produce and respond to b2m; however,
b2m does not affect the release of alkaline phosphatase and/or gene expression of other bone resorbing agents.
The involvement of a variety of cytokines suggests thator osteocalcin by isolated osteoblasts [35]. In agreement
with earlier findings, we also demonstrated that b2m did b2m affects bone formation, as well as bone resorption,
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K, Seo H: Involvement of b2-microglobulin modified with advancedand/or uncouples bone formation from resorption, which
glycation end products in the pathogenesis of hemodialysis-associ-
may result in the cystic bone lesions. ated amyloidosis: Induction of human monocyte chemotaxis and
macrophage secretion of tumor necrosis factor-a and interleukin-1.
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